FDA's bold plan could fast-track gene-editing therapies for rare diseases

The US Food and Drug Administration (FDA) has proposed new guidelines to expedite access to tailored therapies for rare diseases. The move aims to eliminate obstacles for experimental treatments, including advanced gene-editing solutions. Under the plan, therapies tested on a limited number of patients could secure approval more readily than before.

The proposed pathway, dubbed 'plausible mechanism', would apply to well-researched conditions where treatments directly target the disease's genetic or cellular roots. Unlike the current compassionate use process, this route could potentially facilitate the commercialisation of such therapies.

In 2023, a CRISPR-based therapy called CASGEVY (exagamglogene autotemcel) was trialed on 15 patients suffering from sickle cell anemia and beta-thalassemia. Developed by researchers at the Children's Hospital of Philadelphia and the University of Pennsylvania, the treatment was part of clinical trials. The FDA's new approach would consider similar cases where a therapy has successfully addressed a patient's specific genetic or biological abnormality.

Before finalising the rules, the agency will accept public comments on the draft guidance for 60 days. Officials have emphasised that the primary goal is to reduce barriers and stimulate innovation in treatments for rare diseases.

The FDA's proposal could pave the way for more personalised therapies to reach patients sooner. If adopted, the pathway would concentrate on conditions where the underlying biology is clearly understood. Developers of gene-editing and other targeted treatments may soon have a clearer route to approval.